Recent progress in biomolecular engineering

Biotechnology Progress

Volumn 16, Issue 1, 2000, Pages 2-16

  Ryu, Dewey D Y ^a   Nam, Doo Hyun ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMOLECULAR ENGINEERING; BIOMOLECULES; GEL ELECTROPHORESIS; MUTATION;

ANTIBODY LIBRARY; BIOMEDICAL ENGINEERING; BIOMOLECULAR ELECTRONICS; COMBINATORIAL LIBRARY; DNA SHUFFLING; DNA; PHAGE DISPLAY;

CELLS; DISEASES; ELECTROPHORESIS; INDUSTRIAL APPLICATIONS; MASS SPECTROMETRY; MOLECULES; MUTAGENESIS; PATIENT TREATMENT; PROTEINS;

BIOCHEMICAL ENGINEERING;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES; BIOMEDICAL ENGINEERING; BIOTECHNOLOGY; COMPUTATIONAL BIOLOGY; ENZYMES; GENETIC ENGINEERING; HUMANS; IMMUNOTOXINS; MUTAGENESIS, SITE-DIRECTED; PEPTIDE LIBRARY; VACCINES, SYNTHETIC;

EID: 0033963244     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp088059d     Document Type: Review

References (172)

1. Adair, J. R.; Bright, S. M. Progress with Humanized Antibodies - an Update. Expert Opin. Invest. Drugs 1995, 4, 863-870.
2. Adams, G. P.; Schier, R.; Marshall, K.; Wolf, E. J.; McCall, A. M.; Marks, J. D.; Weiner, L M. Increased Affinity Leads to Improved Selective Tumor Delivery of Single-chain Fv Antibodies. Cancer 1998a, 58, 485-490.
3. Adams, G. P.; Schier, R.; McCall, A. M.; Crawford, R. S.; Wolf, E. J.; Weiner, L M.; Marks, J. Prolonged in vivo Tumor Retention Diabody Targeting the Extracellular Domain of Human HER2/neu. Brit. J. Cancer 1998b, 77, 1405-1412.
4. Ahlers, J. D.; Takeshita, T.; Pendleton, C. D.; Berzofsky, J. A. Enhanced Immunogenicity of HIV-1 Vaccine Construct by Modification of the Native Peptide Sequence. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 10856-10861.
5. Akamatsu, Y.; Murphy, J. C.; Nolan, K. F.; Thomas, P.; Kreitman, R. J.; Leung, S. O.; Junghans, R. P. A Single-chain Immunotoxin against Carcinoembryonic Antigen that Suppresses Growth of Colorectal Carcinoma Cells. Clin. Cancer Res. 1998, 4, 2825-2832.
6. Anderson, N. L.; Anderson, N. G. Proteome and Proteomics: New Technologies, New Concepts, and New Words. Electrophoresis 1998, 19, 1853-1861.
7. Andrade, M. A.; Sander, C. Bioinformatics: from Genome Data to Biological Knowledge. Curr. Opin. Biotechnol. 1997, 8, 675-683.
8. Bachelez, H.; Flageul, B.; Dubertret, L.; Fraitag, S.; Grossman, R.; Brousse, N.; Poisson, D.; Knowles, R. W.; Wacholtz, M. C.; Haverty, T. P.; Chatenoud, L.; Bach, J. F. Treatment of Recalcitrant Plaque Psoriasis with a Humanized Nondepleting Antibody to CD4. J. Autoimmun. 1998, 11, 53-62.
9. Balass, M.; Katchaiski-Katzir, E.; Fuchs, S. The α-Bungarotoxin Binding Site on the Nicotinic Acetylcholine Receptor: Analysis Using a Phage-Epitope Library. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 6054-6058.
10. Balland, A.; Courtney, M.; Jallat, S.; Tessier, L. H.; Sondermeyer, P.; de la Salle, H.; Harvey, R.; Degryse, E.; Tolstoshev, P. Use of Synthetic Oligonucleotides in Gene Isolation and Manipulation. Biochimie 1985, 67, 725-736.
11. Ballinger, M. D.; Tom, J.; Wells, J. A. Designing Subtilisin BPN′ to Cleave Substrates Containing Dibasic Residues. Biochemistry 1995, 34, 13312-13319.
12. Ballinger, M. D.; Tom, J.; Wells, J. A. Furilisin: a Variant of Subtilisin BPN′ Engineered for Cleaving Tribasic Substrates. Biochemistry 1996, 35, 13579-13585.
13. Baselga, J.; Norton, L.; Albanell, J.; Kim, Y. M.; Mendelsohn, J. Recombinant Humanized Anti-HER2 Antibody Herceptin Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts. Cancer Res. 1998, 58, 2825-2831.
14. HER2 Monoclonal Antibody in Patients with HER2/neu-overexpressing Metastatic Breast Cancer. J. Clin. Oncol. 1996, 14, 737-744.
15. Bednar, M. M.; Gross, C. E.; Russell, S. R.; Fuller, S. P.; Ellenberger, C. L.; Schindler, E.; Klingbeil, C.; Vexler, V. Humanized Anti-L-selectin Monoclonal Antibody DREG200 Therapy in Acute Thromboembolic Stroke. Neurol. Res. 1998, 20, 403-408.
16. Ben-Yedidia, T.; Arnon, R. Design of Peptide and Polypeptide Vaccines. Curr. Opin. Biotechnol. 1997, 8, 442-448.
17. Ben-Yedidia, T.; Abel, L.; Arnon, R.; Globerson, A. Efficacy of Anti-influenza Peptide Vaccine in Aged Mice. Mech. Ageing Dev. 1998, 104, 11-23.
18. Blazevic, V.; Ranki, A.; Krohn, K. J. Helper and Cytotoxic T Cell Response of HIV Type 1-infected Individuals to Synthetic Peptides of HIV Type 1 Rev. AIDS Res. Hum. Retroviruses 1995, 11, 1335-1342.
19. Belyakov, I. M.; Derby, M. A.; Ahlers, J. D.; Kelsall, B. L.; Earl, P.; Moss, B.; Strober, W.; Berzofsky, J. A. Mucosal Immunization with HIV-1 Peptide Vaccine Induces Mucosal and Systemic Cytotoxic T Lymphocytes and Protective Immunity in Mice against Intrarectal Recombinant HIV-vaccinia Challenge. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 1709-1714.
20. Bocanegra, J. A.; Scrutton, N. S.; Perham, R. N. Creation of an NADP-dependent Pyruvate Dehydrogenase Multienzyme Complex by Protein Engineering. Biochemistry 1993, 32, 2737-2740.
21. Boulianne, G. L.; Hozumi, N.; Shulman, M. J. Production of Functional Chimeric Mouse/Human Antibody. Nature 1994, 312, 643-646.
22. Bowen, J. D.; Petersdorf, S. H.; Richards, T. L.; Maravilla, K. R.; Dale, D. C.; Price, T. H.; St John, T. P.; Yu, A. S. Phase I Study of a Humanized Anti-CD11/CD18 Monoclonal Antibody in Multiple Sclerosis. Clin. Pharmacol. Ther. 1998, 64, 339-346.
23. Brand, D.; Lemiale, F.; Turbica, I.; Buzelay, L.; Brunet, S.; Barin, F. Comparative Analysis of Humoral Immune Responses to HIV Type 1 Envelope Glycoproteins in Mice Immunized with a DNA Vaccine, Recombinant Semliki Forest Virus RNA, or Recombinant Semliki Forest Virus Particles. AIDS Res. Hum. Retroviruses 1998, 14, 1369-1377.
24. Brett, S.; Baxter, G.; Cooper, H.; Johnston, J. M.; Tite, J.; Rapson, N. Repopulation of Blood Lymphocyte Sub-populations in Rheumatoid Arthritis Patients Treated with the Depleting Humanized Monoclonal Antibody, CAMPATH-1H. Immunology 1996, 88, 13-19.
25. Briand, L.; Chobert, J. M.; Gander, R.; Declerck, N.; Tran, V.; Leonil, J.; Molle, D.; Haertle, T. Impact of the Lysine-188 and Aspartic Acid-189 Inversion on Activity of Trypsin. FEBS Lett. 1999, 442, 43-47.
26. Bruggemann, M.; Taussig, M. J. Production of Human Antibody Repertoire in Transgenic Mice. Curr. Opin. Biotechnol. 1997, 8, 455-458.
27. Bruggemann, M.; Caskey, H. M.; Teale, C.; Waldmann, H.; Williams, G. T.; Surani, M. A.; Neuberger, M. S. A Repertoire of Monoclonal Antibodies with Human Heavy-chains from Transgenic Mice. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6709-6713.
28. Buerke, M.; Weyrich, A. S.; Murohara, T.; Queen, C.; Klingbeil, C. K.; Co, M. S.; Lefer, A. M. Humanized Monoclonal Antibody DREG-200 Directed against L-Selectin Projects in Feline Myocardial Reperfusion Injury. J. Pharmacol. Exp. Ther. 1994, 271, 134-142.
29. Caldwell, R. C.; Joyce, G. F. Randomization of Genes by PCR Mutagenesis. PCR Methods Appl. 1994, 2, 28-33.
30. Cane, D. E.; Wash, C. T.; Khosla, C. Harnessing the Biosynthetic Code: Combinations, Permutations, and Mutations. Science 1998, 282, 63-68.
31. Caron, P. C.; Jurcic, J. G.; Scott, A. M.; Finn, R. D.; Divgi, C. R.; Graham, M. C.; Jureidini, I. M.; Sgouros, G.; Tyson, D.; Old, L. J. et al. A Phase 1B Trial of Humanized Monoclonal Antibody M195(Anti-CD33) in Myeloid Leukemia: Specific Targeting without Immunogenecity. Blood 1994, 83, 1760-1768.
32. Carreras, C. W.; Santi, D. V. Engineering of Modular Polyketide Syntheses to Produce Novel Polyketides. Curr. Opin. Biotechnol. 1998, 9, 403-411.
33. Carter, P.; Merchant, A. M. Engineering Antibodies for Imaging and Therapy. Curr. Opin. Biotechnol. 1997, 8, 449-454.
34. Casale, T. B.; Bernstein, I. L.; Busse, W. W.; LaForce, C. F.; Tinkelman, D. G.; Stoltz, R. R.; Dockhorn, R. J.; Reimann, J.; Su, J. Q.; Pick, R. B.; Adelman, D. C. Use of an Anti-IgE Humanized Monoclonal Antibody in Ragweed-induced Allergic Rhinitis. J. Allergy Clin. Immunol. 1997, 100, 110-121.
35. Cassels, F. J.; Jarboc, D. L.; Reid, R. H.; Lees, A.; Deal, C. D. Linear Epitopes of Colonization Factor Antigen I and Peptide Vaccine Approach to Enterotoxigenic Encherichia coli. J. Ind. Microbiol. Biotechnol. 1997, 19, 66-70.
36. Chandrasegaran, S.; Smith, J. Chimeric Restriction Enzymes: What is Next? Biol. Chem. 1999, 380, 841-848.
37. Charpentier, B.; Thervet, E. Placebo-controlled Study of a Humanized Anti-TAC Monoclonal Antibody in Dual Therapy for Prevention of Acute Rejection after Renal Transplantation. Transplant. Proc. 1998, 30, 1331-1332.
38. Chen, L.; Coutinho, P. M.; Nikolov, Z.; Ford, C. Effect of Replacing Helical Glycine Residues with Alanines on Reversible and Irreversible Stability and Production of Aspergillus awamori Glucoamylase. Protein Eng. 1996, 9, 499-505.
39. Chen, S. C.; Jones, D. H.; Fynan, E. F.; Farrar, G. H.; Clegg, J. C. S.; Greenberg, H. B.; Herrmann, J. E. Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles. J. Virol. 1998, 72, 5757-5761.
40. Chobert, J. M.; Briand, L.; Leonil, J.; Moller, D.; Haertle, T. Engineering of Trypsin and Its Impact on β-Casein Processing. Nahrung 1998, 42, 135-138.
41. Cwirla, S. E.; Balasubramanian, P.; Duffin, D. J.; Wagstrom, C. R.; Gates, C. W.; Gates, C. M.; Singer, S. C.: Davis, A. M.; Tansik, R. L.; Mattheakis, L. C.; Boytos, C. M.; Schatz, P. J.; Baccanari, D. P.; Wrighton, N. C.; Barrett, R. W.; Dower, W. J. Peptide Agonist of the Thrombopoietin Receptor as Potent as Natural Cytokine. Science 1997, 276, 1696-1699.
42. Daly, T. M.; Long, C. A. A Recombinant 15-Kilodalton Carboxy-terminal Fragment of Plasmodium yoelii 17XL Merozoit Surface Protein 1 Induces a Protective Immune Response in Mice. Infect. Immunol. 1993, 61, 2462-2467.
43. Das, J.; Kimball, S. D. Thrombin Active Site Inhibitors. Bioorg. Med. Chem. 1995, 3, 999-1007.
44. Da Villa, G.; Pelliccia, M. G.; Peluso, F.; Ricciardi, E.; Sepe, A. Anti-HBs Responses in Children Vaccinated with Different Schedules of Either Plasma-derived or HBV DNA Recombinant Vaccine. Res. Virol. 1997, 148, 109-114.
45. Declerck, N.; Joyet, P.; Trosset, J.-Y.; Garnier, J.; Gaillardin, C. Hyperthermostable Mutants of Bacillus licheniformis α-Amylase: Multiple Amino Acid Replacements and Molecular Modeling. Protein Eng. 1995, 8, 1029-1037.
46. Deck, R. R.; De Witt, C. M.; Donnelly, J. J.; Liu, M. A.; Ulmer, J. B. Characterization of Humoral Immune Responses Induced by an Influenza Hemagglutinin DNA Vaccine. Vaccine 1997, 15, 71-78.
47. De Ferra, F.; Rodriguez, F.; Tortora, O.; Tosi, C.; Grandi, G. Engineering of Peptide Synthetases. J. Biol. Chem. 1997, 272, 25304-25306.
48. Dhainaut, J. F. A.; Vincent, J. L.; Richard, C.; Lejeune, P.; Martin, C.; Fierobe, L.; Stephens, S.; Ney, U. M.; Sopwith, M.; Mercat, A.; Edouard, A.; Friedman, G.; Marin, N.; Schlemmer, B.; Lepape, A.; Novak, C. CDP571, a Humanized Antibody to Human Tumor Necrosis Factor-α - Safety, Pharmacokinetics, Immune Response, and Influence of the Antibody on Cytokine Concentrations in Patients with Septic Shock. Crit. Care Med. 1995, 23, 1461-1469.
49. Disis, M. L.; Gralow, J. R.; Bernhard, H.; Hand, S. L.; Rubin, W. D.; Cheever, M. A. Peptide-based, but not Whole Protein, Vaccines Elicit Immunity to HER-2/neu, Oncogenic Self-protein. J. Immunol. 1996, 156, 3151-3158.
50. Donnelly, J. J.; Friedman, A.; Martinez, D.; Montgomery, D. L.; Shiver, J. W.; Motzel, S. L.; Ulmer, J. B.; Liu, M. A. Preclinical Efficacy of a Prototype DNA Vaccine: Enhanced Protection against Antigenic Drift in Influenza Virus. Nature Med. 1995, 1, 583-587.
51. Everitt, D. E.; Davies, C. B.; Thompson, K.; Dicicco, R.; Ilson, B.; Demuth, S. G.; Herzyk, D. J.; Jorkasky, D. K. The Pharmacokinetics, Antigenecity, and Fusion-inhibition Activity of RSHZ19, a Humanized Monoclonal Antibody to Respiratory Syncytial Virus, in Healthy Volunteers. J. Infect. Dis. 1996, 174, 463-469.
52. Fievet, N.; Maubert, B.; Cot, M.; Chougnet, C.; Dubois, B.; Bickii, J.; Migot, F.; Le Herson, J.; Fronert, Y.; Deloron, P. Humoral and Cellular Immune Responses to Synthetic Peptides from the Plasmodium falciparum Blood-stage Antigen, Pf155/ RESA, in Cameroonian. Clin. Immunol. Immunopathol. 1995, 76, 164-169.
53. Foote, J.; Winter, G. Antibody Framework Residues Affecting the Conformation of the Hypervariable Loop. J. Mol. Biol. 1992, 224, 487-499.
54. Fomsgaard, A.; Nielsen, H. V.; Bryder, K.; Nielsen, C.; Machuca, R.; Bruun, L.; Hansen, J.; Buus, S. Improved Humoral and Cellular Immune Responses against the gp120 V3 Loop of HTV-1 Following Genetic Immunization with a Chimeric DNA Vaccine Encoding the V3 Inserted into the Hepatitis B Surface Antigen. Scand. J. Immunol. 1998, 47, 289-295.
55. Fukumoto, T.; Torigoe, N.; Kawabata, S.; Murakami, M.; Uede, T.; Nishi, T.; Ito, Y.; Sugimura, K. Peptide Mimics of the CTLA4-binding Domain Stimulate T-cell Proliferation. Nature Biotechnol. 1998, 16, 267-270.
56. Garvey, E. P.; Matthews, C. R. Site-directed Mutagenesis and Its Application to Protein Folding. Biotechnology 1990, 14, 37-63.
57. Goh, Y. S.; Lee, J. E.; Oh, K. S.; Bae, D. G.; Chae, C. B. Development of Antiangiogenin Peptide Using a Phage-displayed Peptide Library. Cancer Res. 1997, 57, 3733-3740.
58. Gorse, G. J.; Keefer, M. C.; Belshe, R. B.; Mattews, T. J.; Forrest, B. D.; Hsieh, R. H.; Koff, W. C.; Hanson, C. V.; Dolin, R.; Weinhold, K. J.; Frey, S. E.; Ketter, N.; Fast, P. E. A Dose-ranging Study of a Prototype Synthetic HIV-1 MN V3 Branched Peptide Vaccine. J. Infect. Dis. 1996, 173, 330-339.
59. Goydos, J. S.; Elder, E.; Whiteside, T. L.; Finn, O. J.; Lotze, M. T. A Phase I Trial of a Synthetic Mucin Peptide Vaccine Induction of Specific Immune Reactivity in Patients with Adenocarcinoma. J. Surg. Res. 1996, 63, 298-304.
60. Graycar, T.; Knapp, M.; Ganshaw, G.; Dauberman, J.; Bott, R. Engineered Bacillus lentus Subtilisins having Altered Flexibility. J. Mot. Biol. 1999, 292, 97-109.
61. Hakimi, J.; Mould, D.; Waldmann, T. A.; Queen, C.; Anasetti, C.; Light, S. Development of Zenapax: a Humanized Anti-Tac Antibody. In Antibody Therapeutics; Harris, W. J., Adair, J. R., Eds.; CRC Press: Boca Raton, 1997; pp 277-300.
62. Hamilton, A. A.; Manuel, D. M.; Grundy, J. E.; Turner, A. J.; King, S. I.; Adair, J. R.; White, P.; Carr, F. J.; Harris, W. J. A Humanized Antibody against Human Cytomegalovirus CMV gpUL75 gH for Prophylaxis or Treatment of CMV Infections. J. Infect. Dis. 1997, 176, 59-68.
63. Hayman, W. A.; Brandt, E. R.; Relf, W. A.; Cooper, J.; Saul, A.; Good, M. F. Mapping the Minimal Murine T Cell and B Cell Epitopes within a Peptide Vaccine Candidate from the Conserved Region of the M Protein of Group A Streptococcus. Int. Immunol. 1997, 9, 1723-1733.
64. Haynes, P. A.; Gygi, S. P.; Figeys, D.; Aebersold, R. Proteomic Analysis: Biological Assay or Data Archive? Electrophoresis 1998, 19, 1862-1871.
65. Hedstrom, L.; Szilagyi, L.; Rutter, W. J. Converting Trypsin to Chymotrypsin - the Role of Surface Loops. Science 1992, 255, 1249-1253.
66. Hedstrom, R. C.; Doolan, D. L.; Wang, R.; Gardner, M. J.; Kumar, A.; Sedegah, M.; Gramzinski, R. A.; Sacci, J. B., Jr.; Charoenvit, Y.; Weiss, W. R.; Margalith, M.; Norman, J. A.; Hobart, P.; Hoffman, S. L. The development of a multivalent DNA vaccine for malaria. Springer Sem. Immunopathol. 1997, 19, 147-159.
67. Heppner, D. G.; Gordon, D. M.; Gross, M.; Wellde, B.; Leitner, W.; Krzych, U.; Schneider, I.; Wirtz, R. A.; Richards, R. L.; Trofa, A.; Hall, T.; Sadoff, J. C.; Boerger, P.; Alving, C. R.; Sylvester, D. R.; Porter, T. G.; Ballou, W. R. Safety, Immunogenicity, and Efficacy of Plasmodium falciparum Repeatless Circumsporozoite Protein Vaccine Encapsulated in Liposomes. J. Infect. Dis. 1996, 174, 361-366.
68. Hoffman, S. L.; Doolan, D. L.; Sedegah, M.; Aguiar, J. C.; Wang, R. B.; Malik, A.; Gramzinski, R. A.; Weiss, W. R.; Hobart, P.; Norman, J. A.; Margalith, M.; Hedstrom, R. C. Strategy for Development of a Pre-erythrocytic Plasmodium falciparum DNA Vaccine for Human Use. Vaccine 1997, 15, 842-845.
69. Hsu, S. C.; Shaw, D. M.; Steward, M. W. The Induction of Respiratory Syncytial Virus-specific Cytotoxic T-cell Responses Following Immunization with a Synthetic Peptide Containing a Fusion Peptide Link to a Cytotoxic T-lymphocyte Epitope. Immunology 1995, 85, 347-350.
70. H3) Which Exhibits Rapid, High-level Targeting of Xenografts. Cancer Res. 1996, 56, 3055-3061.
71. Hudson, P. J. Recombinant Antibody Fragments. Curr. Opin. Biotechnol. 1998, 9, 395-402.
72. Huse, W. D.; Sastry, L.; Iverson, S. A.; Kang, A. S.; Alting-Mees, M.; Burton, D. R.; Benkovic, S. J.; Lerner, R. A. Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage λ. Science 1989, 246, 1275-1281.
73. Huygen, K.; Content, J.; Denis, O.; Montgomery, D. L.; Yawman, A. M.; Deck, R. R.; DeWitt, C. M.; Orme, I. M.; Baldwin, S.; D'Souza, C.; Drowart, A.; Lozes, E.; Vandenbussche, P.; Van Vooren, J. P.; Liu, M. A.; Ulmer, J. B. Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine. Nature Med. 1996, 2, 893-898.
74. Hwang, E. S.; Kwon, K. B.; Park, J. W.; Kim, D. J.; Park, C. G.; Cha, C. Y. Induction of Neutralizing Antibody against Human Cytomegalovirus (HCMV) with DNA-mediated Immunization of HCMV Glycoprotein B in Mice. Microbiol. Immunol. 1999, 43, 307-310.
75. Igarashi, K.; Ozawa, T.; Ikawakitayama, K.; Hayashi, Y.; Araki, H.; Endo, K.; Hagihara, H.; Ozaki, K.; Kawai, S.; Ito, S. Thermostabilization by Proline Substitution in an Alkaline, Liquefying α-Amylase from Bacillus sp. strain KSM-1378. Biosci. Biotechnol. Biochem. 1999, 63, 1535-1540.
76. Iliades, P.; Kortt, A. A.; Hudson, P. J. Triabodies: Single Chain Fv Fragments without a Linker Form Trivalent Trimer. FEBS Lett. 1997, 409, 437-441.
77. Isaacs, J. D.; Burrows, N.; Wing, M.; Keogan, M. T.; Rebello, P. R. U. B.; Watts, R. A.; Pye, R. J.; Norris, P.; Hazelman, B. L.; Hale, G.; Waldmann, H. Humanized Anti-CD4 Monoclonal Antibody Therapy of Autoimmune and Inflammatory Disease. Clin. Exp. Immunol. 1997, 110, 158-166.
78. James, P. Protein Identification in the Post-genomic Era: the Rapid Rise of Proteomics. Quart. Rev. Biophys. 1998, 30, 279-331.
79. Johnson, S.; Oliver, C.; Prince, G. A.; Hemming, V. G.; Pfarr, D. S.; Wang, S. C.; Dormitzer, M.; OGrady, J.; Koenig, S.; Tamura, J. K.; Woods, R.; Bansal, G.; Couchenour, D.; Tsao, E.; Hall, W. C.; Young, J. F. Development of a Humanized Monoclonal Antibody MEDI-493 with Potent In Vitro and In Vivo Activity Against Respiratory Syncytial Virus. J. Infect. Dis. 1997, 176, 1215-1224.
80. Juweid, M.; Sharkey, R. M.; Markowitz, A.; Behr, T.; Swayne, L. C.; Dunn, R.; Hansen, H. J.; Shevitz, J.; Leung, S. O.; Rubin, A. D.; Herskovic, T.; Hanley, D.; Goldenberg, D. M. Treatment of Non-Hodgkins Lymphoma with Radiolabeled Murine, Chimeric, or Humanized LL2, an Anti-CD22 Monoclonal Antibody. Cancer Res. 1995, 55, S5899-S5907.
81. Kamath, A. T.; Febg, C. G.; MacDonald, M.; Briscoe, H.; Britton, W. J. Differential Protective Efficacy of DNA Vaccines Expressing Secreted Proteins of Mycobacterium Tuberculosis. Infect. Immunol. 1999, 67, 1702-1707.
82. Kao, C. M.; Luo, G.; Katz, L.; Cane, D. E.; Khosla, C. Manipulation of Macrolide Ring Size by Directed Mutagenesis of a Modular Polyketide Synthase. J. Am. Chem. Soc. 1995, 117, 9105-9106.
83. Kao, C. M.; Luo, G.; Katz, L.; Cane, D. E.; Khosla, C. Engineered Biosynthesis of Structually Diverse Tetraketides by a Tri-modular Polyketide Synthase. J. Am. Chem. Soc. 1996, 118, 9184-9185.
84. Ke, S. H.; Madison, E. L. Rapid and Efficient Site-directed Mutagenesis by Single-tube "Megaprimer" PCR Methodol. Nucleic Acids Res. 1997, 25, 3371-3372.
85. Kim, Y.-G.; Cha, J.; Chandrasefaran, S. Hybrid Restriction Enzymes - Zinc Finger Fusions to FokI Cleavage Domain. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 1156-1160.
86. Kohsla, C.; Zawada, R. J. X. Generation of Polyketide Libraries via Combinatorial Biosynthesis, TIBTECH 1996, 14, 335-341.
87. Kortt, A. A.; Lah, M.; Oddie, G. W.; Gruen, C. L.; Burns, J. E.; Pearce, L. A.; Atwell, J. L.; McCoy, A. J.; Hewlett, G. J.; Metzger, D. W.; Webster, R. G.; Hudson, P. J. Single-chain Fv Fragments of Anti-neuraminidase Antibody NC10 Containing Five- and Ten-residue Linkers Form Dimers and with Zero-residue Linker a Trimer. Protein Eng. 1997, 10, 423-433.
88. Kurth, T.; Grahn, S.; Thormann, M.; Ullmann, D.; Hofmann, H. J.; Jakubke, H. D.; Hedstrom, L. Engineering the S1′ Subsite of Trypsin: Design of a Protease Which Cleaves between Dibasic Residues. Biochemistry 1998, 37, 11434-11440.
89. Kundu, S. K.; Katzenstein, D.; Valentine, F. T.; Spino, C.; Efron, B.; Merigan, T. C. Effect of Therapeutic Immunization with Recombinant gp160 HIV-1 Vaccine on HIV-1 Proviral DNA and Plasma RNA: Relationship to Cellular Immune Responses. J. Acq. Immune Deficiency Syndromes Human Retrovirol. 1997, 15, 269-274.
90. Kuwahara, M.; Sugimoto, M.; Tsuji, S.; Miyata, S.; Nishio, K.; Kaku, S.; Suzuki, K.; Kawasaki, T.; Yoshioka, A. Comparative Studies on the Antiplatelet Effects of a Humanized Antiplatelet Glycoprotein IIb/IIIa Antibody YM337 and ReoPro under Flow Conditions. Thromb. Hemostasis 1998, 80, 28-31.
91. + Cell-depleted BALB/c Mice. J. Virol. 1996, 70, 3084-3092.
92. Lawrence, L. J.; Kortt, A. A.; Iliades, P.; Tulloch, P. A.; Hudson, P. J. Orientation of Antigen Binding Sites in Dimeric and Trimeric Single Chain Fv Antibody Fragments. FEBS Lett. 1997, 425, 479-484.
93. Le, T. P.; Church, L. W. P.; Corradin, G.; Hunter, R. L.; Charoenvit, Y.; Wang, R. B.; delaVega, P.; Sacci, J.; Ballou, W. R.; Kolodny, N.; Kitov, S.; Glenn, G. M.; Richards, R. L.; Alving, C. R.; Hoffman, S. L. Immunogenicity of Plasmodium falciparum Circumsporozoite Protein Multiple Antigen Peptide Vaccine Formulated with Different Adjuvants. Vaccine 1998, 16, 305-312.
94. Lerner, E. C.; Qian, Y.; Blaskovich, M. A.; Fossum, R. D.; Vogt, A.; Sun, J. Z.; Cox, A. D.; Der, C. J.; Hamilton, A. D.; Sebti, S. M. Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes. J. Biol. Chem. 1995, 270, 26802-26806.
95. Levi, R.; Arnon R. Synthetic Recombinant Influenza Vaccine Induces Efficiently Long-term Immunity and Cross-strain Protection. Vaccine 1996, 14, 85-92.
96. Levi, R.; Aboudpirak, E.; Leclerc, C.; Lowell, G. H.; Arnon, R. Intranasal Immunization of Mice against Influenza with Synthetic Peptides Anchored to Proteosome. Vaccine 1995, 13, 1353-1359.
97. Little van den Hurk, S. V.; Braun, R. P.; Lewis, P. J.; Karvonen, B. C.; BacaEstrada, M. E.; Snider, M.; McCartney, D.; Watts, T.; Babiuk, L. A. Intradermal Immunization with a Bovine Herpesvirus-1 DNA Vaccine Induces Protective Immunity in Cattle. J. Gen. Virol. 1998, 79, 831-839.
98. Liu, L.; Yhamchaipenet, A.; Fu, H.; Betlach, M.; Ashley, G. Biosynthesis of 2-Nor-6-deoxyerythronolide B by Rationally Designed Domain Substitution. J. Am. Chem. Soc. 1997, 119, 10553-10554.
99. Lowrie, D. B.; Silva, C. L.; Tascon, R. E. DNA Vaccines against Tuberculosis. Immunol. Cell Biol. 1997, 75, 591-594.
100. Lozes, E.; Huygen, K.; Content, J.; Denis, O.; Montgomery, D. L.; Yawman, A. M.; Vandenbussche, P.; VanVooren, J. P.; Drowart, A.; Ulmer, J. B.; Liu, M. A. Immunogenecity and Efficacy of a Tuberculosis DNA Vaccine Encoding the Components of the Secreted Antigen 85 Complex. Vaccine 1997, 15, 830-833.
101. Macklin, M. D.; McCabe, D.; McGregor, M. W.; Neumann, V.; Meyer, T.; Callan, R.; Hinshaw, V. S.; Swain, W. F. Immunization of Pigs with a Particle-mediated DNA Vaccine to Influenza A Virus Protects against Challenge with Homologous Virus. J. Virol. 1998, 72, 1491-1496.
102. MacGregor, R. R.; Boyer, J. D.; Ugen, K. E.; Lacy, K. E.; Gluckman, S. J.; Bagarazzi, M. L.; Chattergoon, M. A.; Baine, Y.; Higgins, T. J.; Ciccarelli, R. B.; Coney, L. R.; Ginsberg, R. S.; Weiner, D. B. First Human Trial of a DNA-based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response. J. Infect. Dis. 1998, 178, 92-100.
103. Marsden, A. F.; Wilkinson, B.; Cortes, J.; Dunster, N. J.; Staunton, J.; Leadlay, P. F. Engineering Broader Specificity into an Antibiotic-producing Polyketide Synthase. Science 1998, 279, 199-120.
104. Martinelle, M.; Holmquiest, M.; Clausen, I. G.; Patkar, S.; Svensen, A.; Hult, K. The Role of Glu87 and Trp87 in the Lid of Humicola lanuginosa Lipase. Protein Eng. 1996, 9, 519-524.
105. Mata, L.; Gripon, J. C.; Mistou, M. Y. Deletion of the Four C-terminal Residues of PepC Converts an Aminopeptidase into an Oligopeptidase. Protein Eng. 1999, 12, 681-686.
106. Matteson, E. L.; Yocum, D. E.; St. Clair, E. W.; Achkar, A. A.; Thakor, M. S.; Jacobs, M. R.; Hays, A. E.; Heyman, C. K.; Johnston J. M. Treatment of Active Refractory Rheumatoid Arthritis with Humanized Monoclonal Antibody CAMPATH-1H Administered by Daily Subcutaneous Injection. Arthritis Rheum. 1995, 38, 1187-1193.
107. McCafferty, J.; Griffiths, A. D.; Winter, G.; Chiswell, D. J. Phage Antibodies: Filamentous phage Displaying Antibody Variable Domains. Nature 1990, 348, 552-554.
108. McDaniel, R.; Ebert-Khosla, S.; Hopwood, D. A.; Khosla, C. Rational Design of Aromatic Polyketide Natural Products by Recombinant Assembly of Enzyme Subunits. Science 1995, 375, 549-554.
109. Moller, K. Naked DNA for Vaccine or Therapy. J. Mol. Med. 1997, 75, 242-246.
110. Mulder, F. A.; Schipper, D.; Bott, R.; Boelens, R. Altered Flexibility in the Substrate-binding Site of Related Native and Engineered High-alkaline Bacillus subtilisins. J. Mol. Biol. 1999, 292, 111-123.
111. Nashan, B.; Light, S.; Hardie, I. R.; Lin, A.; Johnson, J. Reduction of Acute Renal Allograft Rejection by Daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999, 67, 110-115.
112. Neglia, F.; Orengo, A. M.; Cilli, M.; Meazza, R.; Tomassetti, A.; Canavari, S.; Melani, C.; Colombo, M. P.; Ferrini, S. DNA Vacccination against the Ovarian Carcinoma-associated Antigen Folate Receptor a (FRα) Induces Cytotoxic T Lymphocyte and Antibody Responses in Mice. Cancer Gene Ther. 1999, 6, 349-357.
113. Neuberger, M. S.; Williams, G. T.; Fox, R. O. Recombinant Antibodies Processing Novel Effector Functions. Nature 1994, 312, 604-608.
114. Newton, D. L.; Xue, Y.; Olson, K. A.; Fett, J. W.; Rybak, S. M. Angiogenin Single-chain Immunofusions: Influence of Peptide Linkers and Spacers between Fusion Protein Domain. Biochemistry 1996, 35, 545-553.
115. Nixon, A. E.; Ostermeier, M.; Benkovic, S. J. Hybrid Enzymes: Manipulating Enzyme Design. TIBTECH 1998, 16, 258-264.
116. Null, D.; Bimle, C.; Weisman, L.; Johnson, K.; Steichen, J.; Singh, S.; Wang, E.; Asztalos, E.; Loeffler, A. M.; Azimi, P. H.; Lieberman, J. M.; ODonnell, N. E.; Cooke, R. J.; McCormick, K.; Koo, W. et al. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics 1998, 102, 531-537.
117. Obeid, O. E.; Partidos, C. D.; Howard, C. R.; Steward, M. W. Protection against Morbillivirus-induced Encephalitis by Immunization with a Rationally Designed Synthetic Peptide Vaccine Containing B- and T-Cell Epitopes from the Fusion Protein of Measles Virus. J. Virol. 1995, 69, 1420-1428.
118. Okada, Y.; Yoshigi, N.; Sahar, H.; Koshino, S. Increase in Thermostability of Recombinant Barley α-Amylase by Random Mutagenesis. Biosci. Biotechnol. Biochem. 1995, 59, 1152-1153.
119. Osterborg, A.; Fassas, A. S.; Anagnostopoulos, A.; Dyer, M. J. S.; Catovsky, D.; Mellstedt, H. Humanized CD52 Monoclonal Antibody CAMPATH-1H as First-line Treatment in Chronic Lymphocytic Leukemia. Br. J. Haematol. 1996, 93, 151-153.
120. Ozzello, L.; Blank, E. W.; De Rosa, C. M.; Ceriani, R. L.; Tolo, H.; Kauppinen, H. L.; Cantell, K. Conjugation of Interferon a to a Humanized Monoclonal Antibody HuBrE-3vl Enhances the Selective Localization and Antitumor Effects of Interferon in Breast Cancer Xenografts. Breast Cancer Res. Treat. 1998, 48, 135-147.
121. Pai, L. H.; Wittes, R.; Setser, A.; Willingham, M. C.; Pastan, I. Treatment of Advanced Solid Tumors with Immunotoxin, LMB-1: an Antibody Linked to Pseudomonas Exotoxin. Nature Med. 1996, 2, 350-353.
122. Partidos, C. D.; Vohra, P.; Steward, M. W. Priming of Measles Virus-specific CTL Responses After Immunization with a CTL Epitope Linked to a Fusogenic Peptide. Virology 1996, 215, 107-110.
123. Park, S. S.; Ryu, C. J.; Gripon, P.; Guguen Guillouzo, C.; Hong, H. J. Generation and Characterization of a Humanized Antibody with Specificity for prPS2 Surface Antigen of Hepatitis B Virus. Hybridoma 1996, 15, 435-441.
124. Patarroyo, G.; Franco, L.; Amador, R.; Morillo, L. A.; Rocha, C. A.; Rogha, M.; Patarroyo, M. E. Study of the Safety and Immunogenecity of the Synthetic Malaria Spf66 Vaccine in Children Age 1-14 Years. Vaccine 1992, 10, 175-178.
125. Patten, P. A.; Howard, R. J.; Stemmer, W. P. C. Application of DNA Shuffling to Pharmaceuticals and Vaccines. Curr. Opin. Biotechnol. 1997, 8, 724-733.
126. Pegram, M. D.; Lipton, A.; Hayes, D. F.; Weber, B. L.; Baselga, J. M.; Tripathy, D.; Baly, D.; Baughman, S. A.; Twaddell, T.; Glaspy, J. A.; Slamon, D. J. Phase II Study of Receptor-enhanced Chemosensitivity Using Recombinant Humanized Anti-p185 HER2/neu Monoclonal Antibody Plus Cisplatin in Patients with HER2/neu-overexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment. J. Clin. Oncol. 1998, 16, 2659-2671.
127. Porter, K. R.; Kochel, T. J.; Wu, S. J.; Raviprakash, K.; Phillips, I.; Hayes, C. G. Protective Efficacy of a Dengue 2 DNA Vaccine in Mice and the Effect of CpG Immunostimulatory Motifs on Antibody Responses. Arch. Virol. 1998, 143, 997-1003.
128. Rader, C.; Barbas, C. F, III. Phage Display of Combinatorial Antibody Libraries. Curr. Opin. Biotechnol. 1997, 8, 503-508.
129. Reidhaar-Olson, J.; Bowie, J.; Breyer, R. M.; Hu, J. C.; Knight, K. L.; Lim, W. A.; Mossing, M. C.; Prasell, D. A.; Shoemaker, K. R.; Sauer, R. T. Random Mutagenesis of Protein Sequences Using Oligonucleotide Cassettes. Methods Enzymol. 1991, 208, 564-586.
130. Richard, G.; Fairhead, C.; Dujon, B. Complete Transcriptional Map of Yeast Chromosome XI in Different Life Conditions. J. Mol. Biol. 1997, 268, 303-321.
131. Richards, J.; Auger, J.; Peace, D.; Gale, D.; Michel, J.; Koons, A.; Haverty, T.; Zivin, R.; Jolliffe, L.; Bluestone, J. A. Phase I Evaluation of Humanized OKT3: Toxicity and Immunomodulatory Effects of hOKT3γ4. Cancer Res. 1999, 59, 2096-2101.
132. Rosenberg, S. A.; Yang, J. C.; Schwartzentruber, D. J.; Hwu, P.; Marincola, F. M.; Topalian, S. L.; Restifo, N. P.; Dudley, M. E.; Schwarz, S. L.; Spiess, P. J.; Wunderlich, J. R.; Parkhurst, M. R.; Kawakami, Y.; Seipp, C. A.; Einhorn, J. H.; White, D. E. Immunologic and Therapeutic Evaluation of a Synthetic Peptide Vaccine for the Treatment of Patients with Metastatic Melanoma. Nature Med. 1998, 4, 321-327.
133. Ruan, X.; Pereda, A.; Stassi, D.; Zeidner, D.; Summers, R.; Jackson, M.; Shivakumar, A.; Kakavas, S.; Staver, M.; Donadio, S.; Katz, L. Acyltransferase Domain Substitutions in Erythromycin Polyketide Synthase Yield Novel Erythromycin Derivatives. J. Bacteriol. 1997, 179, 6416-6425.
134. Rubingh, D. N. Engineering Proteases with Improved Properties for Detergent. In Enzyme Technology for Industrial Applications; Savage, L., Southborough, M. A., Eds.; IBI Biomedical Library, 1996; pp 98-123.
135. Sarin, P. S.; Mora, C. A.; Naylor, P. H.; Markham, R.; Schwartz, D.; Kahn, J.; Heseltine, P.; Gazzard, B.; Youle, M.; Rios, A.; Goldstein, A. L. HIV-1 p17 Synthetic Peptide Vaccine HGP-30 - Induction of Immune Response in Human Subjects and Preliminary Evidence of Protection against HIV Challenge in SCID Mice. Cell. Mol. Biol. 1995, 41, 401-407.
136. Samuel, J.; Budzynski, W. A.; Reddish, M. A.; Ding, L.; Zimmermann, G. L.; Krantz, M. J.; Koganty, R. R.; Longenecker, B. M. Immunogenicity and Antitumor Activity of a Liposomal MUC1 Peptide-based Vaccine. Int. J. Cancer 1998, 75, 295-302.
137. Schena, M.; Shalon, D.; Davis, R. W.; Brown, P. O. Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray. Science 1995, 270, 467-470.
138. Schena, M.; Heller, R. A.; Theriault, T. P.; Konrad, K.; Lachenmeier, E.; Davis, R. W. Microarrays: Biotechnology's Discovery Platform for Functional Genomics. TIBTECH 1998, 16, 301-306.
139. Scrutton, N. S.; Berry, A.; Perham, R. N. Redesign of the Coenzyme Specificity of a Dehydrogenase by Protein Engineering. Nature 1990, 343, 38-43.
140. Singh, A.; Hayashi, K. Construction of Chimeric β-Glucosidases with Improved Enzymatic Properties. J. Biol. Chem. 1995, 270, 21928-21933.
141. Smith, G. P. Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Virion Surface. Science 1985, 228, 1315-1317.
142. Smithgall, T. E. SH2 and SH3 Domains: Potential Targets for Anti-cancer Drug Design. J. Pharmacol. Toxicol. Methods 1995, 34, 125-132.
143. Soisson, L. A.; Reid, G. D.; Farah, I. O.; Nyindo, M.; Strand, M. Protective Immunity in Baboons Vaccinated with a Recombinant Antigen or Radiation-attenuated cercariae of Schistosoma mansoni is Antibody-Dependent. J. Immunol. 1993, 151, 3995-4001.
144. Stachelhaus, T.; Schneider, A.; Marahiel, M. A. Rational Design of Peptide Antibiotics by Targeted Replacement of Bacterial and Fungal Domains. Science 1995, 269, 69-72.
145. Stager, S.; Gottstein, B.; Muller, N. Systemic and Local Antibody Response in Mice Induced by a Recombinant Peptide Fragment from Giardia lamblia Variant Surface Protein VSP H7 Produced by a Salmonella typhimurium Vaccine Strain. Int. J. Parasitol. 1997, 27, 965-971.
146. Stemmer, W. P. C. Rapid Evolution of Protein in vitro by DNA Shuffling. Nature 1994a, 370, 389-391.
147. Stemmer, W. P. C. DNA Shuffling by Random Fragmentation and Reassembly: in vitro Recombination for Molecular Evolution. Proc. Natl. Acad. Sci. U.S.A. 1994b, 91, 10747-10751.
148. Steward, M. W.; Partidos, C. D.; D'Mello, F.; Howard, C. R. Specificity of Antibodies Reactive with Hepatitis B Surface Antigen Following Immunization with Synthetic Peptides. Vaccine 1993, 11, 1405-1414.
149. Strausberg, S. L.; Alexander, P. A.; Gallagher, D. T.; Gilliland, G. L.; Barnett, B. L.; Bryan, P. N. Directed Evolution of a Subtilisin with Calcium-independent Stability. Biol/Technol. 1995, 13, 669-673.
150. Svensen, A. Protein Engineering of Microbial Lipases with Industrial Interest. In Enzyme Technology for Industrial Applications; Savage, L., Southborough, M. A. Eds.; IBI Biomedical Library, 1996; pp 98-123.
151. Szardenings, M.; Tornroth, S.; Mutulis, P.; Muceniece, R.; Keinanen, K.; Kuusinen, A.; Wikberg, J. E. Phage Display Selection on Whole Cells Yields a Peptide Specific for Melanocortin Receptor 1. J. Biol. Chem. 1997, 272, 27943-27948.
152. Tarrab-Hazdai, R.; Schechtman, D.; Arnon, R. Synthesis and Characterization of a Protective Peptide-based Vaccine against Schistosoma mansoni. Infect. Immun. 1998, 66, 4526-4530.
153. Tokushige, K.; Wakita, T.; Pachuk, C.; Moradpour; Weiner, D. B.; Zurawski, V. R. Jr; Wands, J. R. Expression and Immune Response to Hepatitis C Virus Core DNA-based Vaccine Constructs. Hepatology 1996, 24, 14-20.
154. Tsunenari, T.; Koishihara, Y.; Nakamura, A.; Moriya, M.; Ohkawa, H.; Goto, H.; Shimazaki, C.; Nakagawa, M.; Ohsugi, Y.; Kishimoto, T.; Akamatsu, K. New Xenograft Model of Multiple Myeloma and Efficacy of a Humanized Antibody against Human Interleukin-6 Receptor. Blood 1997, 90, 2437-2444.
155. Tuteja, R. DNA Vaccines: A Ray of Hope. Crit. Rev. Biochem. Mol. Biol. 1999, 34, 1-24
156. Van den Burg, B.; Vriend, G.; Veltman, O. R.; Venema, G.; Eijsink, V. G. Engineering an Enzyme to Resist Boiling. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 2056-2060.
157. Vaughan, T. J.; Osbourn, J. K.; Tempest, P. R. Human Antibodies by Design. Nature Biotechnol. 1998, 16, 535-539.
158. Venekei, I.; Szilagyi, L.; Graf, L.; Rutter, W. J. Attempts to Convert Chymotrypsin to Trypsin. FEBS Lett. 1996, 379, 143-147.
159. Vincenti, F.; Lantz, M.; Birnbaum, J.; Garovoy, M.; Mould, D.; Hakimi, J.; Nieforth, K.; Light, S. A Phase I Trial of Humanized Anti-interleukin 2 Receptor Antibody in Renal Transplantation. Transplantation 1997, 63, 33-38.
160. Vita, C.; Roumestand, C.; Toma, F.; Menez, A. Scorpion Toxins as Natural Scaffolds for Protein Engineering. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 6404-6408.
161. Wagner, C. R.; Benkovic, S. J. Site Directed Mutagenesis: a Tool for Enzyme Mechanism Dissection. Trends Biotechnol. 1990, 8, 263-270.
162. Wang, R.; Doolan, D. L.; Le, T. P.; Hedstrom, R. C.; Coonan, K. M.; Charoenvit, Y.; Jones, T. R.; Hobart, P.; Margalith, M.; Ng, J.; Weiss, W. R.; Sedegah, M.; de Taisne, C.; Norman, J. A.; Hoffman, S. L. Induction of Antigen-specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine. Science 1998, 282, 476-480.
163. Weinblatt, M. E.; Maddison, P. J.; Bulpitt, K. J.; Hazleman, B. L.; Urowitz, M. B.; Sturrock, R. D.; Coblyn, J. S.; Maier, A. L.; Spreen, W. R.; Manna, V. K.; Johnston, J. M. CAMPATH-1H, a Humanized Monoclonal Antibody, in Refractory Rheumatoid Arthritis - an Intravenous Dose-escalation Study. Arthritis Rheumat. 1995, 38, 1589-1594.
164. Wilks, H. M.; Hart, K. W.; Feeney, R.; Dunn, C. R.; Muirhead, H.; Chia, W. N.; Barstow, D. A.; Atkinson, T.; Clarke, A. R.; Holbrook, J. J. A Specific, Highly Active Malate Dehydrogenase by Redesign of a Lactate Dehydrogenase Framework. Science 1988, 242, 1541-1544.
165. Woodle, E. S.; Bluestone, J. A.; Zivin, R. A.; Jolliffe, L. K.; Auger, J.; Xu, D.; Thistlethwaite, J. R. Humanized, Nonmitogenic OKT3 Antibody, HuOKT3 γ Ala-Ala: Initial Clinical Experience. Transplant. Proc. 1998, 30, 1369-1370.
166. Woychik, R. P.; Klebig, M. L.; Justice, M. J.; Magnuson, T. R.; Avrer, E. D. Functional Genomics in the Post-genome Era. Mutation Res. 1998, 400, 3-14.
167. Wrighton, N. C.; Farrell, F.; Chang, R.; Kashyap, A. K.; Barbone, F. P.; Mulcahy, L. S.; Johnson, D. L.; Barrett, R. W.; Joliffe, L. K.; Dower, W. J. Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin, Science 1996, 273, 458-463.
168. Yap, I.; Guan, R.; Chan, S. H. Study on the Comparative Immunogenecity of a Recombinant DNA Hepatitis B Vaccine Containing Pre-S Components of the HBV Coat Protein with Non Pre-S Containing Vaccines. J. Gastroenterol. Hepatol. 1995, 10, 51-55.
169. Yenari, M. A.; Kunis, D.; Sun, G. H.; Onley, D.; Watson, L.; Turner, S.; Whitaker, S.; Steinberg, G. K. Hu23F2G, an Antibody Recognizing the Leukocyte CD11/CD18 Integrin, Reduces Injury in a Rabbit Model of Transient Focal Cerebral Ischemia. Exp. Neurol. 1998, 153, 223-233.
170. Yoshizaki, K.; Nishimoto, N.; Mihara, M.; Kishimoto, T. Therapy of Rheumatoid Arthritis by Blocking IL-6 Signal Transduction with a Humanized anti-IL-6 Receptor Antibody. Springer Sem. Immunopathol 1998, 20, 247-259.
171. Zweiger, G.; Scott, R. W. From Expressed Sequence Tags to "Epigenomics": an Understanding Disease Processes. Curr. Opin. Biotechnol. 1997, 8, 684-687.
172. Zwick, M. B.; Shen. J.; Scott, J. K. Phage-displayed Peptide Libraries. Curr. Opin. Biotechnol. 1998, 9, 427-436.